PMID: 25465418DOI: 10.1016/j.jacc.2014.09.038Dec 4, 2014Paper

Vorapaxar, combination antiplatelet therapy, and stroke

Journal of the American College of Cardiology
Robert G HartJeffrey I Weitz

Abstract

No abstract listed.

References

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Jan 12, 2002·BMJ : British Medical Journal·UNKNOWN Antithrombotic Trialists' Collaboration

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

Jul 28, 2004·Lancet·Hans-Christoph DienerUNKNOWN MATCH investigators

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

Aug 4, 2007·European Heart Journal·Thomas H WangUNKNOWN CHARISMA Investigators

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

Nov 15, 2011·The New England Journal of Medicine·Pierluigi TricociUNKNOWN TRACER Investigators

Vorapaxar in the secondary prevention of atherothrombotic events

Mar 27, 2012·The New England Journal of Medicine·David A MorrowUNKNOWN TRA 2P–TIMI 50 Steering Committee and Investigators

Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.

Aug 31, 2012·The New England Journal of Medicine·UNKNOWN SPS3 InvestigatorsLesly A Pearce

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial

Aug 31, 2012·Lancet·Benjamin M SciricaUNKNOWN TRA 2°P-TIMI 50 Steering Committee Investigators

Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists

Nov 20, 2012·Stroke; a Journal of Cerebral Circulation·Guido J FalconeJonathan Rosand

Efficacy and safety of vorapaxar in patients with prior ischemic stroke

Feb 12, 2013·Stroke; a Journal of Cerebral Circulation·David A MorrowUNKNOWN Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Inve

Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial

Jun 4, 2013·Lancet·O R BenaventeJ M Szychowski

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack

Jun 28, 2013·The New England Journal of Medicine·Yongjun WangUNKNOWN CHANCE Investigators

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Dec 10, 2013·Lancet·Christian T RuffElliott M Antman

❮ Previous
Next ❯

Citations

Vorapaxar for secondary stroke prevention: perspectives and obstacles

Nov 14, 2015·Expert Review of Neurotherapeutics·Victor L SerebruanyDan F Hanley

Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease

Aug 5, 2016·Nature Reviews. Cardiology·Davide CapodannoDominick J Angiolillo

Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside

Jun 2, 2017·Journal of Cardiovascular Pharmacology and Therapeutics·Jae Youn MoonDominick J Angiolillo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Related Papers

Vorapaxar: targeting a novel antiplatelet pathway.

(opens in new tab)
P & T : a Peer-reviewed Journal for Formulary Management
Younos AbdulsattarDanielle Garcia

Efficacy and safety of vorapaxar in patients with prior ischemic stroke

(opens in new tab)
Stroke; a Journal of Cerebral Circulation
David A MorrowThrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Inve
ContactHelpTerms Privacy Cookies
© 2022 Meta ULC. All rights reserved